| 1.36 -0.02 (-1.45%) | 08-27 15:03 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.69 | 1-year : | 1.97 |
| Resists | First : | 1.45 | Second : | 1.69 |
| Pivot price | 1.34  |
|||
| Supports | First : | 1.21 | Second : | 1.07 |
| MAs | MA(5) : | 1.35 |
MA(20) : | 1.29 |
| MA(100) : | 1.32 |
MA(250) : | 2.59 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 66.9 |
D(3) : | 69.6 |
| RSI | RSI(14): 56.4 |
|||
| 52-week | High : | 4.76 | Low : | 0.85 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SNOA ] has closed below upper band by 47.2%. Bollinger Bands are 70.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.4 - 1.41 | 1.41 - 1.41 |
| Low: | 1.33 - 1.33 | 1.33 - 1.34 |
| Close: | 1.37 - 1.38 | 1.38 - 1.39 |
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
Tue, 25 Aug 2026
Price to book forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Wed, 19 Aug 2026
Sonoma Pharmaceuticals cancels special meeting due to lack of quorum - Investing.com
Sat, 08 Aug 2026
DISCLOSED: Wall Street Just Upgraded These Stocks Vancouver Vs Fc Dallas (P7bWYic7U2) - Mshale
Thu, 06 Aug 2026
Sonoma U.S. Revenue Climbs 141%; First-Ever Positive Adjusted EBITDA - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 5 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 2.3 (%) |
| Shares Short | 8 (K) |
| Shares Short P.Month | 83 (K) |
| EPS | -1.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.72 |
| Profit Margin | -10.4 % |
| Operating Margin | -0.7 % |
| Return on Assets (ttm) | -5.4 % |
| Return on Equity (ttm) | -42.6 % |
| Qtrly Rev. Growth | 59.5 % |
| Gross Profit (p.s.) | 1.78 |
| Sales Per Share | 4.57 |
| EBITDA (p.s.) | -0.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -1.11 |
| PEG Ratio | 1 |
| Price to Book value | 0.78 |
| Price to Sales | 0.29 |
| Price to Cash Flow | -2.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|